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ABSTRACT
This study evaluated the antibacterial efﬁcacy of the consumption of cranberry capsules vs. placebo in
the urine of healthy volunteers. A ﬁrst double-blind, randomised, crossover trial involved eight
volunteers who had followed three regimens, with or without cranberry, with a wash-out period of at
least 6 days between each regimen. Twelve hours after consumption of cranberry or placebo hard
capsules, the ﬁrst urine of the morning was collected. Different Escherichia coli strains were cultured in
the urine samples. Urinary antibacterial adhesion activity was measured in vitro using the human T24
epithelial cell-line, and in vivo using the Caenorhabditis elegans killing model. With the in-vitro model,
108 mg of cranberry induced a signiﬁcant reduction in bacterial adherence to T24 cells as compared with
placebo (p <0.001). A signiﬁcant dose-dependent decrease in bacterial adherence in vitrowas noted after
the consumption of 108 and 36 mg of cranberry (p <0.001). The in-vivo model conﬁrmed that E. coli
strains had a reduced ability to kill C. elegans after growth in the urine of patients who consumed
cranberry capsules. Overall, these in-vivo and in-vitro studies suggested that consumption of cranberry
juice represents an interesting new strategy to prevent recurrent urinary tract infection.
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INTRODUCTION
Each year, urinary tract infections (UTIs) account
for >11 million physician visits in the USA and
2 million in France, and 3.5 million antimicrobial
prescriptions [1,2]. Escherichia coli, the major
pathogen involved in these infections, has devel-
oped new mechanisms of resistance against
b-lactams and ﬂuoroquinolones, which are the
antimicrobial agents that are usually used to treat
UTIs. A novel group of plasmid-mediated
extended-spectrum b-lactamases, the CTX-M
enzymes, has been reported. These enzymes
hydrolyse broad-spectrum cephalosporins, with
higher levels of hydrolytic activity against cefo-
taxime than against ceftazidime, and are inhibited
by suicide inhibitors [3]. The incidence of CTX-M
enzymes has increased dramatically since 1995,
with spread among other enterobacteria, in the
community, and in most parts of the world [3].
These enzymes are now widespread in urinary
E. coli strains, which have thus become multire-
sistant. Moreover CTX-M-producing strains gen-
erally have a high level of resistance to several
other non-b-lactam antibiotic families, particu-
larly the quinolones. It therefore seems essential
to investigate potential new strategies for the
prevention and ⁄ or treatment of UTIs.
In this context, it has been suggested that
consumption of beverages containing cranberry
juice is effective in preventing UTIs [4–6]. This
presumed efﬁcacy is related to the anti-adherent
properties of cranberry juice [7]. Recently, the
effectiveness of cranberry proanthocyanidins and
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cranberry beverages against antibiotic-resistant
E. coli has been described [8]. However, to date,
few experiments have evaluated the effects of the
consumption of cranberry juice on E. coli viru-
lence against uroepithelial cells in vitro. Several
clinical trials have investigated the efﬁcacy of
cranberry juice as prophylaxis against UTI [9], but
the in-vitro and in-vivo effects of commercial
cranberry juice preparations on E. coli virulence
have not yet been documented.
Accordingly, the present study used a rando-
mised double-blind trial to assess inhibitory
activity in the urine of healthy subjects
following consumption of commercial Vaccinium
macrocarpon (cranberry) capsules on the adher-
ence of resistant and susceptible E. coli strains to
human uroepithelial cells. The virulence of the
E. coli strains was also tested in a validated
in-vivo nematode killing model [10].
MATERIALS AND METHODS
Healthy volunteers
Eight healthy female volunteers with a normal diet, aged
30–42 years, who belonged to the nurse population of the Foch
Hospital, Suresnes, France, were included in a double-blind,
randomised, placebo-controlled and crossover study. Admin-
istration of an antibiotic either in the 2-week period before the
study or during the study, or pregnancy, were exclusion
criteria. All volunteers gave informed consent to participate in
the study.
Study protocol
The study was carried out using commercially available
capsules of V. macrocarpon (cranberry) (Urell express; Pharma-
toka, Rueil Malmaison, France) and capsules of placebo. The
commercial cranberry capsules did not contain fructose,
thereby allowing the effect of the proanthocyanidins to be
evaluated. The placebo capsules contained colloidal silica,
magnesium stearate, cellulose and gelatine. Each volunteer
received three successive regimens with her evening meal.
These comprised, in a random order: (i) three capsules of
cranberry (108 mg), or (ii) three capsules of placebo, or (iii) one
capsule of cranberry (36 mg) and two capsules of placebo. The
dose tested in the present study corresponded to the dose used
currently for prevention of UTI (an initial dose of 108 mg, and
36 mg daily thereafter). A wash-out period of at least 6 days
between each regimen was allowed. Twelve hours after
consumption of cranberry or placebo hard capsules, the ﬁrst
urine of the morning was collected, centrifuged at 4000 g for
15 min, sterilised by ﬁltration (0.45-lm ﬁlter), and stored at
)20C.
For the various assays, a collection of four uropathogenic
E. coli strains, isolated previously from patients with symp-
tomatic UTIs [10], was used: NECS20575 and NECS29787,
which are strains with P-ﬁmbriae papG and type 1 pili; NEC5,
a CTX-M-15-producing strain without P-ﬁmbriae and type 1
pili; and NEC13, a TEM-3-producing strain with type 1 pili but
no P-ﬁmbriae.
In-vitro studies
Urinary bacterial anti-adhesion activity following product
consumption was evaluated as described previously [1].
In a ﬁrst assay, strains were subcultured overnight at 37C
to enhance production of P-ﬁmbriae and type 1 pili. Undiluted
urine from each regimen was then incubated for 20 min at
37C with the different bacterial strains at a concentration of
105 CFU ⁄mL (corresponding to the bacterial concentration
indicative of a clinical UTI), and this was followed by tests for
the ability to agglutinate red blood cells using a mannose-
resistant human red blood cell (HRBC) assay [11]. This activity
was determined using a micro-haemagglutination test in
96-well round-bottomed plates in the presence of group A+
or O+ HRBCs newly drawn in citrate tubes. A 3% w ⁄v
suspension of HRBCs was added to each well containing
dilutions of the bacterial ⁄urine suspensions, and the micro-
plate was agitated for 15 min. Each well was then evaluated
microscopically for the presence or absence of haemaggluti-
nation. If the HRBCs in a well were not agglutinated, the urine
in that particular well was considered to have cranberry
metabolites with anti-adhesion activity. The ﬁnal dilution at
which agglutination suppression by the cranberry proantho-
cyanidins present in urine samples occurred was recorded.
Wells containing only the erythrocyte suspension were used as
negative controls. This rapid test evaluated the bacterial anti-
adhesion activity of urine following consumption of Urell
capsules.
In a second assay, in-vitro bacterial adherence experi-
ments were performed with the human T24 epithelial
cell-line (ATCC HTB-4) using an adaptation of the method
of Di Martino et al. [4]. In brief, bacteria were grown
overnight in human urine containing Luria–Bertani broth
5% v ⁄v. Bacterial cells were harvested by centrifugation and
resuspended at 108 CFU ⁄mL in McCoy’s medium, added to
a monolayer of the T24 cell-line, and incubated for 3 h at
37C. After six washes with phosphate-buffered saline, the
cells were ﬁxed in methanol, stained with Giemsa 20% v ⁄v,
and examined microscopically under oil immersion. The
average number of bacteria ⁄T24 cell was determined by
examining 100 T24 cells and was then recorded as the
adhesion index. This index was expressed as a mean of at
least four independent assays.
In-vivo model
The Caenorhabditis elegans infection assay was performed as
described previously [10]. The Fer15 mutant line, which has a
temperature-sensitive fertility defect, was used. The worms
and E. coli strain OP50 (an avirulent control strain) were
provided by J. Ewbank (CIML, Marseille, France). To synchro-
nise the growth of worms, eggs were collected using the
hypochlorite method. NGM plates were inoculated with a
drop of an overnight culture of an E. coli strain and incubated
at 37C for 8)10 h. Plates were allowed to cool to room
temperature and were then seeded with L4-stage worms
(20–30 ⁄plate). The plates were then incubated at 25C and
scored each day for live worms under an MS5 stereomicro-
scope (Leica, Rueil-Malmaison, France). All four E. coli strains
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were tested for their ability to kill C. elegans. At least three
replicate assays, repeated on three occasions, were performed
for each selected clone. A worm was considered to be dead
when it no longer responded to touch.
Statistical analysis
Comparisons among the four E. coli strains, the three regimens
and the two doses were evaluated using a two-way ANOVA
procedure. The normality of the distribution was checked in
each class by using a Shapiro–Wilks test. If an interaction was
signiﬁcant (p <0.05), a one-way ANOVA was performed to
determine the dose effect for each strain and the strain effect
for each regimen. A Student–Newman–Keuls test was used to
evaluate the statistical difference between each pair of groups.
A Cox regression analysis was used to compare the entire
survival curves in nematode killing assays, thereby allowing
the timing of mortality between treatments to be compared. All
analyses were performed using SAS ⁄ETS v.9.1 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Effect detected by in-vitro models
In total, 24 regimens were tested on four E. coli
strains, representing 96 assays. For each group of
strains, four independent trials were performed.
The HRBC screening demonstrated that inhibition
of agglutination occurred for the susceptible
strains grown in urine collected from patients
who had consumed three capsules of cranberry.
This inhibition was dose-dependent (Table 1).
The highest adherence index was obtained with
the susceptible E. coli isolates grown in urine
samples collected after consumption of three
placebo capsules (Table 2). Three capsules of
cranberry preparation caused a highly signiﬁcant
reduction in bacterial adherence to T24 cells as
compared with placebo (p <0.001). There was a
dose-dependent decrease in bacterial adherence
following cranberry intake. The adherence index
obtained with bacteria grown in urine samples
collected after intake of three cranberry capsules
was lower than that observed with one cranberry
capsule (p <0.001), even though a reduction in
adherence was also noted with one cranberry
capsule. The adherence to uroepithelial cells of
the b-lactamase-producing NEC5 and NEC13
strains was also affected by the consumption of
cranberry capsules. Finally, the NECS20575 and
NECS29787 strains, which both produced PapG
adhesin and type 1 ﬁmbriae, adhered more efﬁ-
ciently to T24 cells than did the NEC5 strain,
which did not produce these proteins, or the
NEC13 strain, which produced only type 1 ﬁmb-
riae (p <0.001).
Reduction in virulence
Using the in-vivo model, the mean time at which
50% of the worms were killed (DL50) was
increased signiﬁcantly for strains NECS20575,
NECS29787 and NEC13 grown in urine samples
collected after cranberry intake, as compared with
the same strains grown in urine samples collected
after placebo intake (Table 3). All the worms
infected with susceptible E. coli grown in urine
containing cranberry metabolites were killed in
9 ± 0.25 days, which was signiﬁcantly longer than
the time required to kill worms infected with
E. coli and grown in urine containing placebo
(7.0 ± 0.5 days). This trend was also observed for
the other strains, but the difference was not
signiﬁcant for NEC5, which does not produce
adhesins. Cox regression analysis revealed that an
infection with susceptible E. coli strains grown in
urine containing cranberry metabolites increased
the survival rate of worms by a factor of 4.03
(p <0.00001).
DISCUSSION
Cranberry (V. macrocarpon) has been associated
with the prevention of UTI for nearly 100 years
[12]. A Cochrane Database Systematic Review has
conﬁrmed an interesting association between
cranberry juice consumption and a decrease in
the number of symptomatic UTIs [5]. However,
there is no evidence that cranberry consumption
can be used to treat UTI once an infection is
present, and no beneﬁcial effect was found in the
prevention of UTI among patients with a neuro-
genic bladder [13] or among paediatric patients
[14,15]. The safety of cranberry juice is considered
Table 1. In-vitro inhibition of haemagglutination of hu-
man red blood cells (HRBCs)
Straina
Susceptibility to
b-lactams Adhesins
HRBC assay (titre)b
3Pl
(n = 8)
1UE + 2Pl
(n = 8)
3UE
(n = 8)
NECS20575 S papG+ ⁄ ﬁmH+ 1 ⁄ 128 1 ⁄ 8 0
NECS29787 S papG+ ⁄ ﬁmH+ 1 ⁄ 256 1 ⁄ 8 0
NEC13 TEM-3 papG) ⁄ ﬁmH+ 1 ⁄ 8 1 ⁄ 1 0
NEC5 CTX-M-15 papG) ⁄ ﬁmH) NA NA NA
3Pl, regimen with three capsules of placebo; 1UE + 2Pl, regimen with one cranberry
capsule and two placebo capsules; 3UE, regimen with three cranberry capsules;
NA, not applicable; S, susceptible.
aThe results are representative of at least four independent trials for each strain.
bResults indicate the ﬁnal dilution at which agglutination suppression by the
bacterial suspensions was observed.
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to be excellent, although some adverse effects have
been reported (e.g., a laxative effect [9] and urinary
stones following the consumptionof large amounts
of cranberry juice over a long period [16]).
The effects of a daily dose of cranberry juice
cocktail have been evaluated using ex-vivo and
in-vivo clinical studies [8,17]. These studies
revealed that 240–300 mL of cranberry juice could
prevent recurrence of UTI [12], suggesting that a
dose of <240 mL ⁄day did not provide sufﬁcient
protection. No previous data are available con-
cerning the dosage and efﬁcacy of tablets or
capsules. The present study used two bioassays to
test the anti-virulence effect of commercial cap-
sules of cranberry extract on four E. coli strains
grown in urine samples collected after consump-
tion of the capsules or placebo. Interestingly,
cranberry intake inhibited the adherence of
strains regardless of whether they produced
P-ﬁmbriae and type 1 ﬁmbriae, as well as both
antibiotic-resistant (CTX-M- and TEM-producing)
and susceptible strains. Zafriri et al. [18] have
previously studied the direct effect of cranberry
juice and cranberry juice constituents on the
adherence of E. coli expressing surface lectins of
deﬁned speciﬁcity for yeast, tissue culture cells,
red blood cells and mouse peritoneal
macrophages. The present results conﬁrmed the
existence of a dose-dependent effect on the in-
vitro adherence of E. coli to bladder epithelial
cells, and demonstrated that the administration of
three capsules (108 mg) of cranberry extract
might represent an interesting alternative ap-
proach for the prevention of UTI, followed by a
regimen of one capsule (36 mg) daily.
The cranberry extract comprises the polyphe-
nolic part of the fruit that remains following
removal of the other components of the berry (e.g.,
vegetable ﬁbres and, more particularly, the acids
and sugars of the fruit). The extraction process is
not selective and all the polyphenols contained in
the fruit are retained. During the initial step in the
development of a UTI, E. coli produces hair-like
ﬁmbriae that protrude from the bacterial surface.
These ﬁmbriae carry adhesins that attach to
receptors on uroepithelial cells [9]. Cranberry
extract contains compounds, i.e., the proanthocy-
anidins, that inhibit E. coli adhesins and show
strong inhibitory activity against P-ﬁmbriae
[11,18]. In the present study, the adherence index
(i.e., the number of bacteria adhering to each cell)
represents the activity of an oligomeric fraction
of the proanthocyanidins belonging to type A.
The adherence index following consumption of
Table 2. Results of in-vitro experiments showing a reduction in adherence of Escherichia coli to T24 cells following
cranberry intake by eight volunteers
Strain
Resistance to
b-lactams Adhesins
Adherence index ± SDa
Decrease in
bacterial
adherence (%) pb
3Pl (n = 8) 1UE + 2Pl (n = 8) 3UE (n = 8) 1UE + 2Pl 3UE 3Pl vs. 3UE 3Pl vs. 1UE 1UE vs. 3UE
NECS20575 S papG+ ⁄ ﬁmH+ 22.49 ± 2.47 13.78 ± 2.63 5.61 ± 2.90 38.7 75.1 <0.001 <0.001 <0.001
NECS29797 S papG+ ⁄ ﬁmH+ 22.32 ± 2.22 14.40 ± 2.54 5.76 ± 2.20 35.5 74.2 <0.001 <0.001 <0.001
NEC13 TEM-3 papG) ⁄ ﬁmH+ 7.37 ± 0.77 4.61 ± 0.48 2.84 ± 0.77 37.5 61.5 <0.001 <0.001 <0.001
NEC5 CTX-M-15 papG) ⁄ ﬁmH) 4.84 ± 0.26 3.42 ± 0.49 1.70 ± 0.46 29.3 64.9 <0.001 <0.002 <0.001
pc NECS vs. NEC <0.001 <0.001 0.002
3Pl, regimen with three capsules of placebo; 1UE + 2Pl, regimen with one cranberry capsule and two placebo capsules; 3UE, regimen with three cranberry capsules.
aThe index was calculated following at least four independent trials for each strain.
bComparison using the same strain of different regimens.
cComparison among strains for the same regimen.
Table 3. In-vivo kinetics of killing of Caenorhabditis elegans infected with Esherichia coli strains grown in urine samples
following cranberry intake
Strain
Resistance to
b-lactams Adhesins
DL50 (days) ± SDa Death (days) ± SDa
p3Pl (n = 8) 3UE (n = 8) 3Pl 3UE
NECS20575 S papG+ ⁄ ﬁmH+ 3.21 ± 0.36 5.43 ± 0.22 7 ± 0.25 9.5 ± 0.25 <0.001
NECS29787 S papG+ ⁄ ﬁmH+ 3.03 ± 0.22 5.11 ± 0.40 6.5 ± 0.25 9 ± 0.25 <0.001
NEC13 TEM-3 papG) ⁄ ﬁmH+ 4.76 ± 0.35 5.28 ± 1.24 9 ± 0.25 10 ± 0.25 0.02
NEC5 CTX-M-15 papG) ⁄ ﬁmH) 5.33 ± 0.15 6.21 ± 0.17 11 ± 0.25 11.5 ± 0.25 –
3Pl, regimen with three placebo capsules; 3UE, regimen with three cranberry capsules; DL50, time at which 50% of the worms were killed.
aThe results are means of at least four independent trials on different days and two independent trials on the same day for each strain.
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placebo shows that P-ﬁmbriae account for >85%
of the overall adhesion, since net adhesion via
type 1 ﬁmbria was 2.5 (AINEC13 – AINEC5, 7.3 –
4.8), while that of P-ﬁmbriae and type 1 ﬁmbriae
was 17.5 (AINECS – AINEC5, 22.3 – 4.8). Moreover,
it seems that strains that lack type 1 and
P-ﬁmbriae adhere via an adhesin whose synthesis
is inhibited by urine containing cranberry metab-
olites, suggesting that cranberry extract affects
various ﬁmbriae, but particularly P-ﬁmbriae.
The C. elegans model has been used previously
to study bacterial pathogenicity [19], and it has
been demonstrated that the ability to kill worms
can be used to evaluate the virulence of uropath-
ogenic E. coli [10]. Uropathogenic E. coli strains
are only pathogenic after ingestion by C. elegans,
often exerting their effect in the anterior part of
the worm’s intestine, where they may establish an
intestinal infection. The present study revealed
that reduced ability of uropathogenic E. coli
strains to kill worms correlates with the con-
sumption of cranberry capsules. Bacteria grown
in the urine of individuals who had consumed
cranberry capsules were unable to adhere to the
worms, resulting in reduced killing of the worms.
However, the possibility that worm-speciﬁc viru-
lence factors other than adhesins might be
involved cannot be excluded.
One of the main limitations of this study was
that cranberry proanthocyanidins in urine sam-
ples were not measured. To date, few pharma-
cokinetic studies, and no in-vivo studies, have
been performed on proanthocyanidins because
of the structural complexity of these molecules
and the absence of commercial standards.
Research has shown that proanthocyanidins
reach the urine of humans and mice after
consumption of cranberry juice; thus oral deliv-
ery of 14C-labelled grape proanthocyanidins to
rats resulted in 19% of the dose being excreted
in the urine, and 45% in the faeces [12]. Activity
increased continuously in a regular progression,
peaking at 4–6 h post-consumption, and per-
sisted in the urine for at least 8 h, suggesting
potential protection against bacterial attachment
to the uroepithelium during this period [20]. In
the present study, it was assumed that cran-
berry proanthocyanidins reached the urine of
individuals and formed the active ingredient in
the various tests. However, the possibility of
other explanations, e.g., an enhancement of the
innate immune system, cannot be excluded.
Nevertheless, this approach provides an inter-
esting new strategy for the prevention of recur-
rent urinary tract infections. With the growing
resistance to antibiotics, cranberries can be
viewed as a potentially useful non-pharmaceu-
tical prophylactic remedy.
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